MedTrace Logo

EndoClot for Preventing Rebleeding After Endoscopic Mucosal Resection (EMR)

NCT01735786 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 164

Last updated 2012-11-28

No results posted yet for this study

Summary

Endoscopic mucosal resection (EMR) has been widely used as a diagnostic and treatment techniques of gastrointestinal small lesions. Postoperative rebleeding is one of the common complication following EMR. Several endoscopic hemostasis methods are currently in use. EndoClot® absorbable polysaccharide hemostat (PAPH) as a new hemostasis material was previously used for surgical hemostasis, but the therapeutic effect and safety in endoscopic application remains unknown. This study has been designed to observe the effect of rebleeding prevention after EMR.

Conditions

  • Endoscopic Hemostasis
  • Colonic Polyps

Interventions

DEVICE

EndoClot

EndoClot hemostat is applied immediately after EMR to achieve hemostasis.

Sponsors & Collaborators

  • Xijing Hospital of Digestive Diseases

    lead OTHER

Principal Investigators

  • Zhiguo Liu, M.D. · Xijing Hospital of Digestive Diseases, Xi'an, Shaanxi, China 710032

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-04-30
Primary Completion
2012-02-29
Completion
2012-03-31

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01735786 on ClinicalTrials.gov